Insider · CIK 0001799732
Roy Lester Freeman
director
Files at IKT (Inhibikase Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,640 | $0.00 | $0 | 22,640 | Feb 19, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,854 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,854 | $0.00 | $0 | 21,854 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,138 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,138 | $0.00 | $0 | 1,138 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,780 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,780 | $0.00 | $0 | 3,780 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +6,667 | $0.00 | $0 | 6,667 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,667 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +6,667 | $0.00 | $0 | 6,667 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jan 22, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +344,452 | $0.00 | $0 | 344,452 | Jan 7, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +172,191 | $0.00 | $0 | 172,191 | Jan 7, 2025 |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +316,647 | $0.00 | $0 | 316,647 | Jan 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.